trending Market Intelligence /marketintelligence/en/news-insights/trending/wz3ox9qg8vaupt7rm_yama2 content esgSubNav
In This List

Eton Pharmaceuticals files for IPO on Nasdaq

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Eton Pharmaceuticals files for IPO on Nasdaq

Eton Pharmaceuticals Inc. filed for an IPO to list its common shares on the Nasdaq Capital Market under the symbol ETON.

The Deer Park, Ill.-based pharmaceutical company, which was founded in April 2017, plans to sell shares priced at $6 each.

Eton Pharmaceuticals was initially a wholly-owned subsidiary of San Diego, Calif.-based ophthalmology company Imprimis Pharmaceuticals Inc. Its pipeline includes DS-300, an injectable nutrition product, as well as EM-100, a treatment for a type of eye inflammation called allergic conjunctivitis.

Following a series A preferred stock financing in June 2017, Imprimis' stake reduced to 3.5 million Eton common shares representing about 27% of the company's capital stock.

The company, which is no longer a unit of Imprimis, intends to use the proceeds from the IPO to fund its clinical trials and product development as well as for other general corporate purposes.

National Securities Corp. is acting as underwriter for the offering.